TNX-1800 induced a strong immune response to CoV-2 in non-human primates. Credit: Arek Socha from Pixabay.

Tonix Pharmaceuticals has reported positive preliminary results following the vaccination of non-human primates with its Covid-19 vaccine candidate, TNX-1800.

Data showed that the live attenuated TNX-1800 induced a strong immune response to CoV-2 in non-human primates.

TNX-1800 is a live modified horsepox virus vaccine for percutaneous administration. It is engineered to express the SARS-CoV-2 spike protein and elicit a predominant T cell response.

Vaccine research is carried out in partnership with the Southern Research Institute, the University of Alberta.

The ongoing study is analysing TNX-1800, a modified horsepox virus encoding CoV-2 spike protein over TNX-801, a live horsepox virus vaccine at two doses.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Tonix Pharmaceuticals president and CEO Seth Lederman said: “We are pleased that all eight animals vaccinated with TNX-1800 manifested ‘takes’, a skin reaction which is a validated biomarker of functional T cell immunity, and that vaccination was associated with neutralising antibodies in each case.

“These results encourage us to advance TNX-1800 to human Phase I trials in 2021, when we expect to have Good Manufacturing Practice or cGMP, quality TNX-1800 available.”

Results showed that at day 14 after a single vaccination, all eight of the TNX-1800 vaccinated non-human primates made anti-CoV-2 neutralising antibodies.

The level of neutralising anti-CoV-2 antibody production was similar between the low and high dose TNX-1800 groups.

Furthermore, results showed that TNX-1800 was well tolerated at both doses.

Tonix now plans to conduct the second phase of the study, where the TNX-1800 vaccinated and control animals will be challenged with CoV-2.

The company earlier announced that its manufacturing partner is FUJIFILM Diosynth Biotechnologies.